Welcome to our dedicated page for American Well news (Ticker: AMWL), a resource for investors and traders seeking the latest updates and insights on American Well stock.
About American Well Corporation (Amwell)
American Well Corporation (NYSE: AMWL), widely known as Amwell, is a leading hybrid care enablement platform revolutionizing the healthcare industry by integrating technology to deliver accessible, affordable, and high-quality care. Headquartered in Boston, Amwell operates at the intersection of healthcare and technology, empowering providers, payers, patients, and innovators to seamlessly deliver care across the entire healthcare continuum. The company's platform supports diverse healthcare needs, including urgent care, chronic care management, behavioral health, post-acute care, and healthy living initiatives.
Core Offerings and Business Model
Amwell provides a single, comprehensive platform that combines virtual and in-person care to create a unified healthcare experience. Its offerings include on-demand and scheduled consultations, virtual primary care, musculoskeletal care, dermatology, and chronic disease management. The platform integrates third-party digital health solutions, such as Hello Heart for cardiovascular health and Vida Health for cardiometabolic care, enabling health systems and insurers to offer tailored, cost-effective, and outcome-driven programs to their members.
The company generates revenue through partnerships with over 50 health plans, representing more than 100 million covered lives, and collaborates with leading health systems comprising thousands of hospitals. Its SaaS-based model ensures scalability and adaptability, catering to the evolving needs of healthcare organizations. Amwell's robust ecosystem also includes its affiliated clinical partner, Amwell Medical Group, which delivers behavioral health and therapy services.
Industry Context and Market Position
Operating in the rapidly growing telehealth and digital health industry, Amwell is strategically positioned to address the global shift towards hybrid care delivery. With nearly two decades of experience, the company has established itself as a trusted partner for some of the largest and most sophisticated healthcare organizations worldwide. Its proprietary platform, Amwell Converge™, integrates advanced technologies to enhance care coordination, data exchange, and patient engagement, ensuring efficient and personalized healthcare delivery.
Amwell differentiates itself from competitors like Teladoc Health through its focus on a unified, interoperable platform that supports a wide range of clinical programs. By fostering partnerships with innovative digital health providers, Amwell continuously expands its portfolio, addressing critical health challenges such as obesity, diabetes, and cardiovascular diseases. This collaborative approach positions the company as a key enabler of value-based care models.
Challenges and Strategic Focus
As a pioneer in digital healthcare, Amwell faces challenges such as ensuring data security, navigating regulatory complexities, and driving adoption across diverse patient populations. The company addresses these challenges by investing in robust cybersecurity measures, aligning with industry standards, and leveraging its extensive network of partners to enhance accessibility and affordability.
Amwell's strategic focus on hybrid care delivery underscores its commitment to transforming healthcare. By integrating virtual and in-person services, the company aims to bridge care gaps, improve clinical outcomes, and reduce costs for patients and healthcare organizations alike. This approach aligns with industry trends emphasizing whole-person care and personalized health solutions.
Conclusion
American Well Corporation is at the forefront of digital healthcare innovation, enabling its clients to deliver seamless, patient-centric care. With its comprehensive platform, strategic partnerships, and commitment to hybrid care, Amwell is well-positioned to shape the future of healthcare delivery. Its emphasis on scalability, interoperability, and clinical excellence ensures it remains a valuable partner for health systems, insurers, and employers seeking to navigate the evolving healthcare landscape.
Amwell (NYSE: AMWL) has appointed Dan Zamansky as its new chief product and technology officer, effective March 03, 2025. Zamansky, an Amazon veteran with over a decade of experience, will lead the company's product and R&D organizations.
At Amazon, Zamansky founded and led AWS Health AI, the company's cloud initiative focused on democratizing AI technology access for healthcare customers. He also managed product and technology teams across AWS and Amazon Ads initiatives.
In his new role, Zamansky will focus on Amwell's technology-enabled care platform for payers and health systems, ensuring its evolution to meet increasing online care demands. He succeeds Vaughn Paunovich, who has served since 2022 and led the company through a re-platforming phase.
Amwell (NYSE: AMWL) has announced the issuance of Restricted Stock Units (RSUs) to four new employees as employment inducements. The grants, approved by the company's Compensation Committee, total 16,737 shares of Class A common stock. The vesting schedule includes 25% of RSUs vesting on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over the following three years, contingent on continued employment. These grants were made under Amwell's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08.
Amwell (NYSE: AMWL), a leading SaaS-based healthcare platform provider, has announced its participation in the TD Cowen 24th Annual Health Care conference in Boston. Dr. Ido Schoenberg, Amwell's chairman and CEO, will engage in a fireside chat on March 4 at 9:10 a.m. ET, along with one-on-one meetings during the conference. Investors can access the audio webcast of the fireside chat through the company's investor relations website at investors.amwell.com.
Amwell (NYSE: AMWL), a provider of SaaS-based technology-enabled healthcare platform, has announced its financial results for the fourth quarter and full year 2024. The company will discuss these results during a conference call scheduled for February 12, 2025, at 5 p.m. ET. Investors can access the earnings report through Amwell's investor relations website, and a live audio webcast of the conference call will be available. A replay of the call will be accessible via webcast on the investor relations website after the event.
Amwell (NYSE: AMWL) has announced it will release its fourth quarter and full year 2024 operating results after market close on Wednesday, February 12, 2025. The company will host a conference call and webcast at 5:00 PM ET on the same day, where management will discuss the financial results and provide business updates. The earnings report and webcast will be accessible through the Investors section of Amwell's website, with a replay available for approximately 90 days at investors.amwell.com.
Amwell (NYSE: AMWL) has announced the addition of Vida Health to its clinical programs portfolio, expanding its virtual cardiometabolic care offerings. The new program, Amwell Cardiometabolic Care Powered by Vida, will provide obesity and diabetes care services, including GLP-1s and anti-obesity medications, through Amwell's platform to health plans and employers.
The program will offer personalized care considering social factors like food security, financial barriers, and cultural norms. Vida's services will integrate with Amwell's existing virtual primary care, urgent care, and behavioral health programs. The partnership aims to address the significant healthcare challenge of obesity, which affects over 40% of American adults and, combined with diabetes, costs the U.S. healthcare system more than $500 billion annually.
The collaboration focuses on delivering value-based, outcomes-driven care through lifestyle interventions and Medical Nutrition Therapy, providing members with a unified entry point for clinical and behavioral health support.
Amwell (NYSE: AMWL) has announced the sale of its Amwell Psychiatric Care (APC) business to Avel eCare for approximately $21M in cash, plus an additional earn-out payment. The divestment includes APC technology, personnel, and the Asana psychiatric clinical network.
The strategic move aims to sharpen Amwell's focus on key growth areas and its unified digital care platform. Through Amwell Medical Group (AMG), the company will continue providing behavioral health services, including AMG Therapy Services and SilverCloud digital behavioral health.
Amwell has reiterated its 2024 guidance, projecting:
- Revenue between $247-252 million
- Adjusted EBITDA between ($137)-($142) million
- AMG visits between 1.4-1.5 million
The company maintains its goal of achieving positive cash flow in 2026.
Amwell (NYSE: AMWL) has announced that CFO Mark Hirschhorn will expand his role to include Chief Operating Officer responsibilities, effective January 1, 2025. While maintaining his CFO duties, Hirschhorn will oversee operational and growth strategies, including clinical, sales, and marketing teams. The company aims to streamline its portfolio and pursue profitable growth, targeting cash flow positivity by 2026.
As part of the organizational restructuring, two executives will depart at year-end: Chief Commercial and Growth Officer Kathy Weiler and current COO Kurt Knight. Weiler contributed to cost initiatives and growth organization transformation, while Knight's 14-year tenure included key roles in strategy, M&A, IPO, COVID-19 operations scaling, and managing Amwell Medical Group.
Amwell (NYSE: AMWL) announced equity compensation grants to new employees under its Inducement Plan. The company granted 254,227 restricted stock units (RSUs) to Mark Hirschhorn, its new CFO, with 25% vesting immediately and the remaining 75% vesting quarterly over three years. Hirschhorn is also eligible for an additional $5 million grant subject to EBITDA targets and company valuation goals, vesting annually over four years. Additionally, 5,084 RSUs were granted to two other new employees, with 25% vesting after one year and the remaining 75% vesting quarterly over three years.
Amwell (NYSE: AMWL), a leading provider of healthcare software as a service, reported its third quarter 2024 financial results for the period ending Sept. 30, 2024. The company will host a conference call today at 5 p.m. ET to discuss these results. The call can be accessed via a live audio webcast on Amwell's investor relations website or by dialing 1-888-510-2008 for U.S. participants and 1-646-960-0306 for international participants, using conference ID number 7830032. A replay will be available shortly afterward on the same website.
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
What does American Well Corporation (Amwell) do?
How does Amwell generate revenue?
What makes Amwell different from competitors like Teladoc Health?
What are Amwell's key focus areas?
Who are Amwell's primary clients?
What challenges does Amwell face in its industry?
What is Amwell's approach to hybrid care delivery?
How does Amwell integrate third-party solutions into its platform?
What is Amwell Converge™?
What is Amwell's role in value-based care models?
